Andriy Derkach
Associate Attending Biostatistician
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (34)
Menin inhibitors (MENINi) show promise for relapsed or refractory (R/R) acute myeloid leukemia (AML) with KMT2A rearrangements (KMT2Ar) and nucleophosmin 1 mutations (NPM1c). Outcomes after MENINi failure are poorly understood. To characterize the mutational landscape and subsequent outcomes, we conducted a multicenter retrospective study of adults from 4 US centers with R/R AML after MENINi failure (relapse after response or primary refractory). The 84 patients (63% KMT2Ar, n = 53; 23% NPM1c, n = 19) who received MENINi were heavily pretreated: 86% (n = 72) had previous intensive chemotherapy (IC) and 77% venetoclax (VEN; n = 67). After MENINi failure, 40% of patients (n = 34) received supportive care. For the treated patients (n = 50), common regimens included hypomethylating agent (HMA)/VEN (26%, n = 13), clinical trial (26%, n = 13), and gilteritinib-based therapy (18%, n = 9). The complete response (CR)/CR with incomplete hematologic recovery (CRi) rate for nontrial therapies was 19% (n = 7); overall response rate was 32% (n = 12). All CR/CRi occurred with HMA/VEN (n = 2, 15%), IC + VEN (n = 4, 67%), or MENINi switching (bleximenib to revumenib, n = 1 [50%]). No patient with FLT3-ITD mutation responded to gilteritinib (0/6 gilteritinib-naïve). Median overall survival from start of next therapy was 4.4 months and superior for patients who achieved CR/CRi, (15.4 vs 3.4 months, P = .048). Outcomes after MENINi failure are poor, but responses occur with VEN-based regimens or MENINi switching. FLT3-ITD, WT1, and MEN1 mutations are associated with resistance.
Year:
2026
Multiple myeloma (MM) is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). While these precursor conditions are asymptomatic, they are not entirely benign and carry a lifelong risk of progression to MM. Unlike other cancers defined by pathology, malignant transformation from MGUS or SMM to MM has so far relied on demonstration of clinical end-organ damage as morphology and cytogenetics cannot reliably distinguish them. In this study, using genomic data from 374 patients with MGUS or SMM (277 training, 97 validation), to our knowledge, we demonstrate for the first time the ability to identify malignant transformation in MGUS and SMM. We introduce the concept of genomic MM and genomic MGUS to differentiate the subsets of MGUS and SMM that are biologically malignant with genomic features indistinguishable from MM from the subset that is premalignant and unlikely to progress to malignancy. Importantly, we find that most SMM has biological features of malignant transformation indistinguishable from MM. As expected, this subset that we consider having genomic MM is associated with a high risk of progression to MM although some patients remained progression-free beyond 5 years. Conversely, 60% of MGUS and 10% of SMM have no evidence of malignant transformation (genomic MGUS), with no progression during follow-up. Integration of genomic features with the 2/20/20 International Myeloma Working Group model significantly improved the prediction of progression among genomic MM. These findings support the use of genomic criteria to refine the classification and the risk stratification in myeloma precursor conditions.
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (63)
Esteban Braggio
Assistant Professor
Mayo Clinic
Montserrat Garcia-Closas
Professor of Epidemiology
Institute of Cancer Research
Kanika Arora
Senior Computational Biologist II
Sloan Kettering Institute
Christopher A. Haiman
University of Southern California
Olivier Elemento
Professor
Weill Cornell Medical College
Christine Ambrosone
Roswell Park Comprehensive Cancer Center
Jennifer Hu
Professor
University of Miami
Matthew Pianko
Clinical Associate Professor
University of Michigan
Katherine Nathanson
Professor
University of Pennsylvania
Xiao‐Ou Shu
Vanderbilt University Medical Center
Yasmin Abaza
Assistant Professor of Medicine
Northwestern Medicine
Justin Cross
Sloan Kettering Institute
Ola Landgren
Professor of Medicine
Sylvester Comprehensive Cancer Center, University of Miami
Shiv Prakash Verma
Senior Research Scientist
Memorial Sloan Kettering Cancer Center
Sergio Giralt
Chief Attending, Adult BMT Service
Memorial Sloan Kettering Cancer Center
Brian Ball
Assistant Clinical Professor
City of Hope
Giancarlo Castellano
Fondazione IRCCS Istituto Nazionale dei Tumori
Louise Brinton
Branch Chief
National Cancer Institute
Stefan Ambs
Senior Investigator (tenured) and Head of the Molecular Epidemiology Section
National Cancer Institute
Dale Sandler
Branch Chief
National Institute of Environmental Health Sciences
Alexandra Kovach
Director, Hematopathology; Associate Professor, Keck School of Medicine of University of Southern California
Children's Hospital of Los Angeles
Julie R Palmer
Boston University School of Medicine
Urvi Shah
Assistant Attending, Myeloma Service
Memorial Sloan Kettering Cancer Center
Wei Zheng
-
Gunjan Shah
Memorial Sloan Kettering Cancer Center
Gladys Block
University of California, Berkeley
Stephen Chanock
National Institutes of Health
Alison Margaret Dunning
University of Cambridge
Qiuyin Cai
Professor
Vanderbilt University Medical Center
Bachisio Ziccheddu
Sylvester Comprehensive Cancer Center, University of Miami
Matthew Barth
Clinical Associate Professor
University at Buffalo State University of New York School of Medicine and Biomedical Sciences
Setor Amuzu
Memorial Sloan Kettering Cancer Center
Melissa A. Troester
Professor
University of North Carolina at Chapel Hill
Jonathan Peled
Director
Memorial Sloan Kettering Cancer Center
GUOCHONG JIA
Vanderbilt University
Andrew Olshan
University of North Carolina at Chapel Hill
Esther John
Professor
Stanford University School of Medicine
Charles F. Lynch
-
Lisa Giulino-Roth
Weill Cornell Medicine
Dezheng Huo
University of Chicago
Gordon Watt
Junior Group Leader
The Netherlands Cancer Institute
Niccolò Bolli
Associate Professor
University of Milan
Saad Usmani
Chief Attending
Memorial Sloan Kettering Cancer Center
Xingyi Guo
Associate Professor
Vanderbilt University Medical Center
Terzah Horton
Associate Professor
Baylor College of Medicine
Jirong Long
Professor
Vanderbilt University Medical Center
Sridevi Rajeeve
Memorial Sloan Kettering Cancer Center
Maximilian Merz
Memorial Sloan Kettering Cancer Center
Wenbin Xiao
Memorial Sloan Kettering Cancer Center
Craig H. Moskowitz
University of Miami Miller School of Medicine
Hira Mian
-
Anita D'Souza
Medical College of Wisconsin
Yaohua Yang
Assistant Professor
University of Virginia
Hamza Hashmi
Memorial Sloan Kettering Cancer Center
Francesco Maura
Assistant Professor
Sylvester Comprehensive Cancer Center
Jian Gu
The University of Texas MD Anderson Cancer Center
Olufunmilayo I. Olopade
Professor
University of Chicago
Thomas Ahearn
Staff Scientist
National Cancer Institute
Christopher Li
Fred Hutchinson Cancer Research Center
Juan-José Garcés
Research Scholar
Sloan Kettering Institute
Seth Wiafe
Assistant Professor
Loma Linda University
Patrick Blaney
Senior Bioinformatics Programmer
NYU Langone Health
William D Figg
Senior Investigator, Lab Chief, Associate Director
National Institutes of Health
Make your next move.
Prepare your application
Review drafts before you send them.